Evolution News and Research

RSS

AccessClosure enters agreement with Benrikal Services for Bengal Radial Compression Band distribution

AccessClosure, Inc., the market leader in extravascular closure devices, announced today an exclusive agreement with Benrikal Services to distribute the Bengal Radial Compression Band in the United States.

29 Sep 2010

Morphotek announces first therapeutic monoclonal antibody for clinical development

Morphotek, Inc., a subsidiary of Eisai Inc., today announced that a monoclonal antibody has been selected for advancement to clinical development under the terms of its March 2009 collaboration agreement with Human Genome Sciences, Inc.

29 Sep 2010

PolyMedix begins PMX-30063 Phase 2 clinical trial for bacterial infections

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 2 clinical trial in Canada with its novel defensin-mimetic antibiotic, PMX-30063.

28 Sep 2010

Endo Pharmaceuticals to acquire Qualitest Pharmaceuticals

Apax Partners today announced that Endo Pharmaceuticals has entered into a definitive agreement to acquire Qualitest Pharmaceuticals for approximately $1.2 billion in cash. Qualitest, a portfolio company of Apax Partners since 2007, is the sixth largest generic pharmaceutical company in the U.S.

28 Sep 2010

Endo Pharmaceuticals to acquire Qualitest Pharmaceuticals

Endo Pharmaceuticals announced today that it has entered into a definitive agreement to acquire Qualitest Pharmaceuticals, a leading, privately held generics company in the U.S., for approximately $1.2 billion in cash.

28 Sep 2010

Axolotl introduces Elysium Discover tool designed for Health Information Exchanges

Axolotl Corp., the nationwide leader in health information exchange services and solutions, today introduced Elysium Discover, the industry's first comprehensive suite of reporting and analytic tools designed specifically for Health Information Exchanges.

27 Sep 2010

Signaling pathway inhibition enhances autologous bone marrow transplant: Research

Identification of a molecular communications pathway that influences the mobilization of hematopoietic (blood) stem cells could lead to targeted therapies for improving bone marrow transplant success rates.

27 Sep 2010

Researchers publish evidence behind evolution of jaws in vertebrates

A half-billion years ago, vertebrates lacked the ability to chew their food. They did not have jaws. Instead, their heads consisted of a flexible, fused basket of cartilage.This week, an international team of researchers led by a faculty member from the University of Colorado at Boulder published evidence that three genes in jawless vertebrates might have been key to the development of jaws in higher vertebrates.

27 Sep 2010

Past exposure to pathogens leads to disease resistance spreading through populations

A study by researchers at Royal Holloway, University of London, University College London and Oxford University, has found that a genetic variant which reduces the chance of contracting diseases such as tuberculosis and leprosy is more prevalent in populations with long histories of urban living.

24 Sep 2010

New iPhone application for breast cancer patients

Nonprofit Breastcancer.org has launched an iPhone application for breast cancer patients. The Breast Cancer Diagnosis Guide is a free mobile app that walks users through the breast cancer pathology report a vital report that sets the patient's treatment path.

23 Sep 2010

St. Jude Medical to highlight OCT product platform at TCT meeting

St. Jude Medical, Inc., a global medical device company, will highlight recently launched technology, including its new Optical Coherence Tomography (OCT) product platform, at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C.

23 Sep 2010

Genomic imprinting can influence carrier's selfish or altruistic behavior

If you are more inclined to love thyself than thy neighbor, it could be your mother's fault. Those are the findings of Francisco -beda, assistant professor of ecology and evolutionary biology at the University of Tennessee, Knoxville.-beda, along with fellow evolutionary biologist Andy Gardner from Oxford University, examined the impact that genomic imprinting has on the carrier's selfish or altruistic behavior.

23 Sep 2010

FDA grants priority review status for Endo’s oxymorphone oral formulation

Endo Pharmaceuticals announced that it recently received notification from the U.S. Food and Drug Administration (FDA) that Endo's new drug application (NDA) for its new oral formulation of long-acting oxymorphone, which is designed to be crush resistant, has been granted priority review status.

23 Sep 2010

Telomere length associated with higher rate of relapse and lower overall survival in aplastic anemia patients

Among patients receiving immunosuppressive therapy for severe aplastic anemia (a condition in which the bone marrow is unable to produce blood cells), the length of telomeres (chromosome markers of biological aging) was not related to the response to treatment but was associated with a higher rate of relapse (return to low blood cell counts) and lower overall survival, according to a study in the September 22/29 issue of JAMA.

22 Sep 2010

St. Jude Medical announces positive subset data results for Angio-Seal Evolution Vascular Closure Device Registry

St. Jude Medical, Inc., a global medical device company, today announced subset data results for the Angio-Seal™ Evolution™ Vascular Closure Device Registry. The results reaffirm the excellent sealing performance of the Angio-Seal Evolution vascular closure device in patients undergoing routine diagnostic and interventional cardiac catheterization procedures.

22 Sep 2010

FDA guides Apricus Bio on RayVa's approvability for Raynaud's syndrome secondary to scleroderma

Apricus Biosciences, backed by a revenue-generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing partnerships, announced today that the U.S. Food and Drug Administration (FDA) has provided guidance on the clinical requirements for assessing the approvability of RayVa for the treatment of Raynaud's syndrome secondary to scleroderma.

22 Sep 2010

Trius and Scripps to develop antibiotics from marine biomedical sources

In an effort to tap into the vast potential of the oceans as a source for novel medical treatments, the Defense Threat Reduction Agency (DTRA), a part of the Department of Defense (DoD), has awarded San Diego-based Trius Therapeutics, Inc. a four-and-a-half year contract worth up to $29.5 million to collaborate with Scripps Institution of Oceanography at UC San Diego for the development of novel antibiotics directed against microorganisms that cause serious infections.

21 Sep 2010

USP PET results qualify Apricus Bio's NexACT as anti-microbial preservative

Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing partnerships, today announced that results from a United States Pharmacopeia Preservative Efficacy Test (USP PET) qualified NexACT as an anti-microbial preservative. The results show that NexACT was effective in killing more than 23 strains of bacteria, fungus and mold, well beyond the requirements for passing the USP PET.

21 Sep 2010

GTRI becomes Veriwave Gold Certified Partner for leveraging WaveDeploy solution

Global Technology Resources, Inc., a Colorado-based I.T. integration consulting group, has announced a formal agreement with one of its strategic partners, VeriWave Inc., making GTRI one of only a handful of Gold Certified Partners in the country. By being a Gold Certified Partner, this gives GTRI the ability to advance its healthcare professional services offerings to the next level.

21 Sep 2010

Endo Pharmaceuticals completes tender offer of Penwest Pharmaceuticals' shares

Endo Pharmaceuticals today announced the successful completion of the tender offer by its indirect wholly owned subsidiary, West Acquisition Corp., for all of the outstanding shares of common stock of Penwest Pharmaceuticals Co.

21 Sep 2010

Evolution News and Research

AccessClosure enters agreement with Benrikal Services for Bengal Radial Compression Band distribution

Morphotek announces first therapeutic monoclonal antibody for clinical development

PolyMedix begins PMX-30063 Phase 2 clinical trial for bacterial infections

Endo Pharmaceuticals to acquire Qualitest Pharmaceuticals

Endo Pharmaceuticals to acquire Qualitest Pharmaceuticals

Axolotl introduces Elysium Discover tool designed for Health Information Exchanges

Signaling pathway inhibition enhances autologous bone marrow transplant: Research

Researchers publish evidence behind evolution of jaws in vertebrates

Past exposure to pathogens leads to disease resistance spreading through populations

New iPhone application for breast cancer patients

St. Jude Medical to highlight OCT product platform at TCT meeting

Genomic imprinting can influence carrier's selfish or altruistic behavior

FDA grants priority review status for Endo’s oxymorphone oral formulation

Telomere length associated with higher rate of relapse and lower overall survival in aplastic anemia patients

St. Jude Medical announces positive subset data results for Angio-Seal Evolution Vascular Closure Device Registry

FDA guides Apricus Bio on RayVa's approvability for Raynaud's syndrome secondary to scleroderma

Trius and Scripps to develop antibiotics from marine biomedical sources

USP PET results qualify Apricus Bio's NexACT as anti-microbial preservative

GTRI becomes Veriwave Gold Certified Partner for leveraging WaveDeploy solution

Endo Pharmaceuticals completes tender offer of Penwest Pharmaceuticals' shares

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News